Jan 29, 2020
Immutep Activities Report
Jan 08, 2020
Immutep Expands Part C of TACTI-002 Due to Positive Data
Dec 18, 2019
INSIGHT-004 Clinical Trial Update
Nov 13, 2019
Immutep Announces European Patent Grant for LAG525 Antibody
Nov 07, 2019
Immutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC
Oct 28, 2019
Operational Update
Oct 14, 2019
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
Oct 09, 2019
Immutep Announces Data Presentations at Upcoming Industry Conferences
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
Sep 25, 2019
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
Sep 22, 2019
Immutep to Receive £4M Milestone Payment from GSK
Sep 16, 2019
Immutep Announces Japanese Patent Grant for LAG525 Antibody
Aug 21, 2019
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
Aug 06, 2019
Immutep Completes A$6M Entitlement Offer
Jul 26, 2019
